Identification and clinical relevance of an oxytocin-deficient state: randomized, crossover, placebo-controlled pilot physiopathological study: GLP1 Study.

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515588-67-00

Enrollment

Registered

2024-06-26

Start date

2021-06-10

Completion date

2024-08-02

Last updated

2024-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypopituarism

Brief summary

Pattern of OT hormone secretion after administration of the study agent (GLP1 vs. placebo).

Detailed description

Secondary variables will be those related to the results of validated questionnaires for the assessment of mood, alexithymia, impulsivity, quality of life, eating behavior and sexual function and their associations with OT secretion parameters.

Interventions

DRUGByetta 10 micrograms solution for injection in pre-filled pen

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Pattern of OT hormone secretion after administration of the study agent (GLP1 vs. placebo).	—

Secondary

Measure	Time frame
Secondary variables will be those related to the results of validated questionnaires for the assessment of mood, alexithymia, impulsivity, quality of life, eating behavior and sexual function and their associations with OT secretion parameters.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026